scorecardresearch
Add as a preferred source on Google
Saturday, April 25, 2026
TopicCipla

Topic: Cipla

New injectable to treat complex, antibiotic-resistant UTIs now in India. All about plazomicin

Prevalence of UTIs in Indian population is estimated to be around 33%. Men have less than 15% chance of developing this infection in their lifetime compared to 60% in case of women.

Cipla set to bring Afrezza, 1st inhalable insulin since Exubera, to Indian markets by 2025

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, received CDSCO approval this week.

Who is Jasdeep Singh Gill, new spiritual head of Punjab’s powerful Dera Beas

An IIT Delhi and Cambridge alumnus, Gill will take over from Gurinder Singh Dhillon. Dera Radha Soami Satsang Beas wields significant influence in Punjab.

Cipla’s US unit recalls 6 bronchospasm inhaler batches over container defect

Cipla advises consumers to discontinue use, return or discard the inhalers, and report any adverse reactions to the U.S. health agency.

Godrej, Cipla, Tata— private archives are filling the gaps in the story of modern India

The National Archives of India has almost no record of India's Green Revolution but National Centre for Biological Sciences in Bangalore does.

Using ‘4IR’ tech to beat global challenges — why 4 Indian firms are on WEF’s ‘lighthouses’ list

Cipla, Dr Reddy’s Lab, Mondelez & Unilever lauded for transition to fourth industrial revolution using advanced technologies despite global challenges like Ukraine war & Covid.

Drugmaker Cipla eyes acquisitions in India, US after Covid windfall

Cipla says it's open to mergers & acquisitions. It may partner with smaller firms working on mRNA platforms after the technology came to the fore during the pandemic.

Only boycott of British goods won’t do — Why Abdul Hamied went on to create Cipla

In 'Caring For Life: The Cipla Story Since 1935', Tulsi Vatsal writes about how Khwaja Abdul Hamied wanted to create a science-based industry for India.

Cipla to experiment with Covid drug remdesivir composition to reduce effect on kidneys

Government's subject expert committee asks Cipla to assess renal toxicity of remdesivir's new formulation through a bioequivalence study as well as clinical trials.

India could be producing over 20,000 vials of Remdesivir per day by month-end: Govt data

Remdesivir is now being manufactured by Cipla, Hetero Labs and Mylan. Cipla Wednesday launched the drug under the brand name Cipremi.

On Camera

Hormuz crisis won’t replace the dollar with yuan. De-dollarisation is a myth

Recent data does not support any dramatic shift away from the dollar. As per IMF, the share of international transactions conducted in dollars has declined from 56.90% to 56.77%.

Haryana’s new industrial policy in the works, but industry says old problems remain unsolved

Increase in employment subsidy, Rs 500 crore for estate revamp, new townships in pipeline—but land cost, power breakdowns and inspector raj top among key worries for industry leaders.

Military pushes for private participation in space, more Indian satellites. ‘Can’t rely on single entity’ 

CDS Anil Chauhan says future space capability will not be built by government agencies alone. ‘It will be co-developed with industry, start-ups, and technology innovators’.

Trump, Netanyahu’s Iran gamble: The regime change rebound

American objectives are unmet. They neither have muscle nor motivation to resume the war. As for Iran, the regime didn’t just survive, it’s now led by more radical individuals.